Bright Green Corporation (BGXX) - Utang jangka dawa marang modal

Bright Green Corp - logo grafis emiten BGXX

This daily price chart for Bright Green (BGXX) on the GURU.Markets platform reflects the asset's dynamics, with a value of 0.00. Bright Green collaborates with US universities and government agencies, supplying pure cannabinoids for scientific research. The business relies on expanding its network of certified greenhouses for B2B pharmaceutical sales. However, risk persists due to the pending government licenses and high cash burn in the absence of stable revenue.

brightgreen.us (BGXX) - Utang jangka dawa marang modal saka 28.04.2023 nganti 21.09.2024

Rincian analitis perusahaan Bright Green Corp. (BGXX)

- rega saiki lan proyeksi nilai saham:
Kurs saham Bright Green Corp|BGXX - Prakiraan konsensus analis
- indikator kapitalisasi pasar:
Kapitalisasi pasar Bright Green Corporation|BGXX - Nilai Total Perusahaan
- rincian nilai buku perusahaan:
Nilai Akuntansi Saham Bright Green|BGXX - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih brightgreen.us|BGXX - Aset Agregat Perusahaan
- data liabilitas lan likuiditas perusahaan:
Utang marang Modal Bright Green|BGXX - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Bright Green Corp|BGXX - Gunggung utang perusahaan|Rasio utang-utang marang kapitalisasi buku Bright Green Corporation|BGXX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Bright Green|Rasio jangkoan perantara brightgreen.us
- indikator bathi lan kelipatan valuasi:
BGXX - Bathi resik perusahaan
Ringkesan analisis perusahaan:brightgreen.us (BGXX)
Produk asli Bright Green

Attracting top-tier biologists to Bright Green (BGXX) requires significant investments in innovative infrastructure and stock option programs. This long-term debt financial leverage ratio compares obligations with a maturity of over one year against equity. The metric determines the biotech's dependence on external borrowing versus internal financing. This chart reflects the balance between credit risk and leverage efficiency. The final value impacts the issuer's overall market capitalization.

Pesaing wigati

Rasio utang jangka dawa marang modal INDV (Indivior plc)|Utang jangka dawa marang modal COLL|Utang jangka dawa marang modal Cronos Corp (CRON)|Utang jangka dawa marang ekuitas Canopy Growth CGC|Koefisien utang jangka dawa marang modal HITI|Aurora - Utang jangka dawa marang modal|Achieve Life Sciences Inc. (ACHV) - Rasio utang jangka dawa marang ekuitas|Skye Bioscience, Inc. (SKYE) - Utang jangka dawa marang ekuitas|Kewajiban jangka dawa marang modal Anebulo Pharma (ANEB)|Rasio utang jangka dawa marang ekuitas INCR|NTRB: Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal NSRX|IGC: Kewajiban jangka dawa marang ekuitas|Utang jangka dawa marang modal MIRA (MIRA Pharmaceuticals, Inc.)|Utang jangka dawa marang modal Flora Growth Inc FLGC|IMCC - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal ADIL (Adial Pharmaceuticals)|artelobio.com (ARTL) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang ekuitas Ensysce Biosciences, Inc.|TTNP (Titan Pharmaceuticals Inc.) - Utang jangka dawa marang modal|Utang jangka dawa marang ekuitas GNLN|Utang jangka dawa marang ekuitas InMed Pharmaceuticals (INM)|AKAN (akandacorp.com) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal ENVB (Enveric Biosciences, Inc.)|Rasio tanggungan utang jangka dawa marang modal hempaccoinc.com (HPCO)